Description |
Bimosiamose is a pan-selectin antagonist, inhibits E-, P-, and L-selectin with IC50s of 88 μM, 20 μM, and 86 μM, respectively, and can be used in the research of inflammatory disease.
|
Related Catalog |
|
Target |
IC50: 88 μM (E-selectin), 20 μM (P-selectin), 86 μM (L-selectin)[1]
|
In Vitro |
Bimosiamose is a pan-selectin antagonist, inhibits E-, P-, and L-selectin with IC50s of 88 μM, 20 μM, and 86 μM, respectively, and can be used in the research of inflammatory disease[1].
|
In Vivo |
Bimosiamose (25 mg/kg, i.v.) significantly improves the survival in rats subjected to severe hepatic ischemia and reperfusion. Bimosiamose also causes lower ALT enzyme levels and decreases neutrophil infiltration[1].
|
References |
[1]. Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72.
|